PDCD1 and melanoma: And the combination therapy of mRNA-4157 vaccines with pembrolizumab, a humanized antibody that selectively blocked the binding of programmed cell death protein 1 (PD-1) on T cells (44), has demonstrated promising efficacy in patients with resected melanoma (43).